HomePharmacologyAntiplatelet

Antiplatelet

View Category

Antiplatelet

TCT 2023 | COMPARE 60/80 HBR TRIAL

This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet...
solaci -
Learn More
Acute coronary syndromes

TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome

This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to:...
solaci -
Learn More
Antiplatelet

Anti-Lipid Therapy in PCI Patients: Monotherapy with Statins or Combination?

According to several studies, in patients with high-risk atherosclerotic disease, such as those affected by coronary artery...
solaci -
Learn More
Antiplatelet

ESC 2023 | Extended Monotherapy with Clopidogrel vs. DAPT in High-Risk Patients

An increasing number of patients currently present both an elevated ischemic risk and hemorrhagic risk. This means...
solaci -
Learn More
Antiplatelet

ESC 2023 | STOPDAPT-3 

Short Dual antiplatelet therapy (DAPT), one to three months, followed by P2Y12 inhibitor monotherapy has been shown...
solaci -
Learn More
Antiplatelet

SOLACI-SBHCI 2023 | Patient-centered Selection Anti-platelet Treatment for ACS-PCI Patients: Real World Evidence of Prasugrel – Dr. Roxana Mehran

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Roxana...
solaci -
Learn More
Antiplatelet

SOLACI-SBHCI 2023 | Is very short DAPT safe in HBR patients undergoing complex PCI – Dr. Marco Valgimigli

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Marco...
solaci -
Learn More
Antiplatelet

Secondary Prevention with P2Y12 Inhibitors: How Consolidated Is This Long Term Alternative vs. Aspirin?

Secondary prevention with P2Y12 inhibitors vs aspirin monotherapy in CAD patients Antiaggregation therapy plays a central role at...
solaci -
Learn More